These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31704880)

  • 1. Immune-Focusing Properties of Virus-like Particles Improve Protective IgA Responses.
    Onodera T; Hashi K; Shukla RK; Miki M; Takai-Todaka R; Fujimoto A; Kuraoka M; Miyoshi T; Kobayashi K; Hasegawa H; Ato M; Kelsoe G; Katayama K; Takahashi Y
    J Immunol; 2019 Dec; 203(12):3282-3292. PubMed ID: 31704880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
    Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
    Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.
    Hjelm BE; Kilbourne J; Herbst-Kralovetz MM
    Hum Vaccin Immunother; 2014; 10(2):410-6. PubMed ID: 24280723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
    Ramani S; Neill FH; Ferreira J; Treanor JJ; Frey SE; Topham DJ; Goodwin RR; Borkowski A; Baehner F; Mendelman PM; Estes MK; Atmar RL
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28249841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
    Bessa J; Schmitz N; Hinton HJ; Schwarz K; Jegerlehner A; Bachmann MF
    Eur J Immunol; 2008 Jan; 38(1):114-26. PubMed ID: 18081037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.
    Heinimäki S; Malm M; Vesikari T; Blazevic V
    J Immunol Res; 2018; 2018():3487095. PubMed ID: 29682589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.
    LoBue AD; Thompson JM; Lindesmith L; Johnston RE; Baric RS
    J Virol; 2009 Apr; 83(7):3212-27. PubMed ID: 19176631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
    Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM
    Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.
    Ko EJ; Lee Y; Lee YT; Jung YJ; Ngo VL; Kim MC; Kim KH; Wang BZ; Gewirtz AT; Kang SM
    Vaccine; 2019 Jun; 37(26):3426-3434. PubMed ID: 31101421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
    Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Clin Immunol; 2018 Dec; 197():110-117. PubMed ID: 30244152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles.
    Tamminen K; Huhti L; Koho T; Lappalainen S; Hytönen VP; Vesikari T; Blazevic V
    Immunology; 2012 Jan; 135(1):89-99. PubMed ID: 22044070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.